

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ann Marie Schmidt and David Stern

Serial No. : 09/167,705 Examiner: F. Hamud

Filing Date : October 6, 1998 Art Unit: 1646

For



EXTRACELLULAR NOVEL RAGE BINDING PROTEIN
(EN-RAGE) AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
January 7, 2000

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same content as that submitted herewith as **Exhibit B** entitled "Sequence Listing."

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Jane M. Love".

Jane M. Love, Ph.D.
Registration No. 42,812
c/o Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

C

SEQUENCE LISTING

T0480' <110> Schmidt, Ann Marie
Stern, David

<120> Extracellular Novel RAGE Binding Protein (EN-RAGE) and
Uses Thereof

<130> 0575/55873

<140> 09/167,705

<141> 1998-10-06

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 395

<212> DNA

<213> Bovine

<400> 1

atgactaagc tggaggacca cctggaggga atcatcaaca tcttccacca gtactccgtt 60
cgggtggggc atttcgacac cctcaacaag cgtgagctga agcagctgat cacaaaggga 120
acttcccaaaa accctccaga acaccaaaga ccaacctacc attgacaaaa tattccaaga 180
cctggatgcc gataaagacg gagccgtcag ctttgaggaa ttcgtagtcc tgggtgtccag 240
ggtgctgaaa acagcccaca tagatatcca caaagagtag gtttccagca atgttcccaa 300
gaagacttac ctttctcctc cctgaggctg ctccccgagg gagagagaat tataaacgta 360
ctttggcaaa ttcttagcaa aaaaaaaaaa aaaaaa 395

<210> 2

<211> 50

<212> PRT

<213> Human

<220>

<221> UNSURE

<222> (47)

<223> Xaa at this position is unknown

<400> 2

Thr Lys Leu Glu Asp His Leu Glu Gly Ile Ile Asn Ile Gly His Gln
1 5 10 15

Tyr Ser Val Arg Val Gly His Phe Asp Thr Leu Asn Lys Tyr Glu Leu
20 25 30

Lys Gln Leu Gly Thr Lys Glu Leu Pro Lys Thr Leu Gln Asn Xaa Lys
35 40 45

Asp Gln
50

<210> 3
<211> 90
<212> PRT
<213> Human

<400> 3
Thr Lys Leu Glu Asp His Leu Glu Gly Ile Ile Asn Ile Phe His Gln
1 5 10 15

Tyr Ser Val Arg Val Gly His Phe Asp Thr Leu Asn Lys Arg Glu Leu
20 25 30

Lys Gln Leu Ile Thr Lys Glu Leu Pro Lys Thr Leu Gln Asn Thr Lys
35 40 45

Asp Gln Pro Thr Ile Asp Lys Ile Phe Gln Asp Leu Asp Ala Asp Lys
50 55 60

Asp Gly Ala Val Ser Phe Glu Glu Phe Val Val Leu Val Ser Arg Val
65 70 75 80

Leu Lys Thr Ala His Ile Asp Ile His Lys
85 90

<210> 4
<211> 18
<212> PRT
<213> Human

<400> 4
Asp Gly Ala Val Ser Phe Glu Glu Phe Val Val Leu Val Ser Arg Val
1 5 10 15

Leu Lys

<210> 5
<211> 5

<212> PRT
<213> Human

<400> 5

Ala Gln Asn Ile Thr
1 5